Kevin Sermet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kevin Sermet has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ady Assaf
Service des maladies infectieuses et tropicales CHU Lille Lille France
1 shared publication - Céline Goeminne
CHU Lille, Unité de Transplantation et Assistance Cardiaque, Lille, France
1 shared publication - David Beauvais
Hematology Department, CHU Lille, Lille, France
1 shared publication Emilie Fréalle
Department of Parasitology-Mycology, CHU Lille, Lille, France
1 shared publication- Emmanuel Faure
Service Universitaire de maladies infectieuses - Hôpital Hutiez, CHU de Lille, Lille, France
1 shared publication - Fanny Vuotto
Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Lille , F-59000 Lille
1 shared publication
Latest Publications
- 29 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15109
Reliability of QuantiFERON®‐CMV in predicting CMV recurrence in heart transplant recipients: A single‐center retrospective study
Background: Recurrence after Cytomegalovirus (CMV) infection in heart transplant recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could reduce this burden; however, its duration remains unestablished. We evaluated the QuantiFERON®‐CMV test to see if it could predict CMV recurrence and help optimize the duration of secondary prophylaxis.Methods: This observational retrospective single center study included all heart transplant recipients who developed CMV infection between 2019 and 2021, with the CD8+ T‐cell‐mediated CMV immunity QuantiFERON®‐CMV test assessed at the time of (val)ganciclovir curative treatment completion. The main outcomes were CMV recurrence and duration of secondary prophylaxis. Secondary outcomes included immunosuppressive regimen, rejection, lymphocyte count, CMV viral load, infection type, and duration as possible confounding factors for recurrence.Results: Among the 15 patients included, five (33%) experienced recurrence, of whom three (60%) had a positive QuantiFERON®‐CMV test. The duration of secondary prophylaxis was similar regardless of QF‐CMV positivity. No confounding factor was significantly associated with CMV recurrence; however, it occurred in only 1/7 (14%) of the patients receiving an everolimus‐containing immunosuppressive regimen.Conclusion: In the population of heart transplant recipients, most of whom received ATG‐based induction, the QuantiFERON®‐CMV assay may not accurately predict CMV recurrence and would have not helped refining the duration of secondary prophylaxis in our patients. Other cell‐mediated immunity tests and strategies in this specific population, including everolimus‐containing regimens, may help predict and manage CMV recurrence.
- 29 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15109
Reliability of QuantiFERON®‐CMV in predicting CMV recurrence in heart transplant recipients: A single‐center retrospective study
Background: Recurrence after Cytomegalovirus (CMV) infection in heart transplant recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could reduce this burden; however, its duration remains unestablished. We evaluated the QuantiFERON®‐CMV test to see if it could predict CMV recurrence and help optimize the duration of secondary prophylaxis.Methods: This observational retrospective single center study included all heart transplant recipients who developed CMV infection between 2019 and 2021, with the CD8+ T‐cell‐mediated CMV immunity QuantiFERON®‐CMV test assessed at the time of (val)ganciclovir curative treatment completion. The main outcomes were CMV recurrence and duration of secondary prophylaxis. Secondary outcomes included immunosuppressive regimen, rejection, lymphocyte count, CMV viral load, infection type, and duration as possible confounding factors for recurrence.Results: Among the 15 patients included, five (33%) experienced recurrence, of whom three (60%) had a positive QuantiFERON®‐CMV test. The duration of secondary prophylaxis was similar regardless of QF‐CMV positivity. No confounding factor was significantly associated with CMV recurrence; however, it occurred in only 1/7 (14%) of the patients receiving an everolimus‐containing immunosuppressive regimen.Conclusion: In the population of heart transplant recipients, most of whom received ATG‐based induction, the QuantiFERON®‐CMV assay may not accurately predict CMV recurrence and would have not helped refining the duration of secondary prophylaxis in our patients. Other cell‐mediated immunity tests and strategies in this specific population, including everolimus‐containing regimens, may help predict and manage CMV recurrence.
- 25 July 2022
- Published by Elsevier in Journal of Medical Mycology
- Vol. 32 (4) , 101312
A case of subacute bowel obstruction revealing slowly-evolutive gastro-intestinal mucormycosis following allogeneic hematopoietic cell transplantation
- 25 July 2022
- Published by Elsevier in Journal of Medical Mycology
- Vol. 32 (4) , 101312
A case of subacute bowel obstruction revealing slowly-evolutive gastro-intestinal mucormycosis following allogeneic hematopoietic cell transplantation